Company Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 24/06/2025 BST			5-day change	1st Jan Change
1,335.00 ^DKK	-1.33%		-7.36%	-10.55%

06-17	Genmab A/S, Q1 2025 Earnings Call, May 08, 2025
06-16	Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	MT

Business description: Genmab A/S

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (80.6%);

- income from research and development (9.3%);

- other (10.1%): primarily income from partnership agreement.

At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Number of employees: 2,638

Sales by Activity: Genmab A/S

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology	10.11B	8.48B	14.6B	16.47B	21.53B

See all business segments

Geographical breakdown of sales: Genmab A/S

Fiscal Period: December	2020	2021	2022	2023	2024
Denmark	10.11B	8.48B	14.6B	16.05B	19.78B
United States of America	-	-	-	380M	902M
Japan	-	-	-	41M	841M

See all geographic segments

Executive Committee: Genmab A/S

Manager	Title	Age	Since
Jan van de Winkel CEO	Chief Executive Officer	64	31/05/2010
Anthony Pagano DFI	Director of Finance/CFO	47	29/02/2020
Rayne Waller CTO	Chief Tech/Sci/R&D Officer	-	15/08/2024
Tahamtan Ahmadi CTO	Chief Tech/Sci/R&D Officer	52	31/01/2021
Andrew Carlsen IRC	Investor Relations Contact	-	-

See GENMAB A/S governance

Composition of the Board of Directors: Genmab A/S

Director	Title	Age	Since
Anders Gersel Pedersen BRD	Director/Board Member	74	31/10/2003
Pernille Erenbjerg BRD	Director/Board Member	58	31/12/2014
Paolo Augusto Paoletti BRD	Director/Board Member	74	31/12/2014
Rolf K. Hoffmann BRD	Director/Board Member	65	31/12/2016
Deirdre Connelly CHM	Chairman	64	25/03/2020
Mijke Zachariasse BRD	Director/Board Member	52	28/03/2019
Elizabeth O'Farrell BRD	Director/Board Member	60	28/03/2022
Martin Schultz BRD	Director/Board Member	50	31/12/2021

Composition of the Board of Directors

Shareholders: Genmab A/S

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.89 %	3,237,113	4.89 %	677 M kr
GENMAB A/S 3.825 %	2,532,038	3.825 %	529 M kr
Jan van de Winkel 0.9526 %	630,588	0.9526 %	132 M kr
Nykredit Bank A/S (Investment Management) 0.4886 %	323,430	0.4886 %	68 M kr
Danske Bank A/S (Investment Management) 0.3307 %	218,911	0.3307 %	46 M kr

Name	Equities	%	Valuation
AllianceBernstein LP 2.224 %	14,725,158	2.224 %	308 M kr
Orbis Investment Management Ltd. 0.8627 %	5,710,741	0.8627 %	120 M kr
Citadel Securities GP LLC 0.6687 %	4,426,654	0.6687 %	93 M kr
Aperio Group LLC 0.5115 %	3,385,857	0.5115 %	71 M kr
Harding Loevner LP 0.4352 %	2,880,826	0.4352 %	60 M kr

List of GENMAB A/S shareholders

Holdings: Genmab A/S

Name	Equities	%	Valuation
GENMAB A/S 3.82%	2,532,038	3.82%	529,258,357 $

Company details: Genmab A/S

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GENMAB A/S	-1.33%	-7.36%	-26.04%	-40.19%	12.91B
REGENERON PHARMACEUTICALS, INC.	+2.02%	+2.64%	-50.91%	-14.73%	54.09B
ARGENX SE	+4.81%	+3.30%	+20.44%	+45.23%	32.84B
WUXI APPTEC CO., LTD.	+2.41%	+0.51%	+65.36%	-34.90%	26.08B
BIONTECH SE	+2.02%	+0.11%	+21.34%	-21.60%	25.36B
INSMED INCORPORATED	+0.46%	+5.60%	+54.76%	+394.40%	20.02B
SUMMIT THERAPEUTICS INC.	+2.60%	+5.39%	+161.50%	+1,735.09%	15.14B
WUXI BIOLOGICS (CAYMAN) INC.	+3.67%	-1.17%	+114.53%	-67.10%	12.7B
EXELIXIS, INC.	+5.42%	+10.55%	+104.84%	+105.76%	11.83B
AKESO, INC.	+2.52%	+3.77%	+155.50%	+283.50%	10.89B
Average	+2.46%	+0.98%	+62.13%	+238.55%	22.19B
Weighted average by Cap.	+2.48%	+1.69%	+34.96%	+163.93%